Villalpando Beija K, Wyles Saranya P, Schaefer Lauren A, Bodiford Katherine J, Bruce Alison J
Mayo Clinic Alix School of Medicine, Rochester, MN 55905, USA.
Department of Dermatology, Mayo Clinic, Rochester, MN 55905 USA.
Plast Aesthet Res. 2021;8. doi: 10.20517/2347-9264.2021.86. Epub 2021 Dec 5.
Evaluate the clinical effectiveness of platelet-rich plasma as a treatment for lichen sclerosus.
A systematic review was performed. The electronic databases PubMed, Ovid MEDLINE, Web of Science, Cochrane, clinicaltrials.gov were used to identify case studies, case series, prospective uncontrolled, and randomized controlled studies published between 1946 and April 21, 2021. Six prospective uncontrolled studies, one randomized double-blind prospective study, and one case report were included.
Platelet-rich plasma treatment was subjectively reported to improve quality of life, but objective measures demonstrating treatment efficacy were not observed. In addition, platelet-rich plasma preparation and administration between studies lacked standardization.
Platelet-rich plasma may be used for symptomatic adjuvant treatment of lichen sclerosus, though additional double-blind controlled studies with standardized platelet-rich plasma protocols are needed to better characterize the efficacy of platelet-rich plasma.
评估富血小板血浆治疗硬化性苔藓的临床疗效。
进行了一项系统评价。使用电子数据库PubMed、Ovid MEDLINE、Web of Science、Cochrane、clinicaltrials.gov来识别1946年至2021年4月21日期间发表的病例研究、病例系列、前瞻性非对照研究和随机对照研究。纳入了六项前瞻性非对照研究、一项随机双盲前瞻性研究和一份病例报告。
主观报告称富血小板血浆治疗可改善生活质量,但未观察到证明治疗效果的客观指标。此外,不同研究之间富血小板血浆的制备和给药缺乏标准化。
富血小板血浆可用于硬化性苔藓的症状性辅助治疗,不过需要更多采用标准化富血小板血浆方案的双盲对照研究,以更好地明确富血小板血浆的疗效。